Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune Diseases - Quiz - MDSpire

Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune Diseases

  • By

  • Dagna Constenla

  • Germain Lonnet

  • Emmanuel Aris

  • Ramsanjay Rk

  • Nathalie Servotte

  • Agnes Mwakingwe-Omari

  • Hannah Alsdurf

  • Huifeng Yun

  • August 11, 2025

  • 0 min

Share

Original Source(s)

Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune Diseases

  • by Dagna Constenla, Germain Lonnet, Emmanuel Aris, Ramsanjay Rk, Nathalie Servotte, Agnes Mwakingwe-Omari, Hannah Alsdurf, Huifeng Yun

  • August 11, 2025

Related Content

Bioinformatics-driven insights: rapamycin-mediated CaMK2D inhibition alleviates intestinal ischemia-reperfusion injury

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.